Evidence map›Paper›PMID 36230663›Full record

ArticleCancers2022

A Large Case-Control Study Performed in Spanish Population Suggests That

Erik Michel Marchena-Perea, Milton Eduardo Salazar-Hidalgo, Alicia Gómez-Sanz, Mónica Arranz-Ledo, Alicia Barroso, Victoria Fernández, Hugo Tejera-Pérez, Guillermo Pita, Rocío Núñez-Torres, Luz Pombo and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Erik Michel Marchena-PereaHuman Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0002-3650-0387
Milton Eduardo Salazar-HidalgoHuman Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0001-8472-1355
Alicia Gómez-SanzMolecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
Mónica Arranz-LedoCancer Genetics Group, Unidad de Excelencia Instituto de Biología y Genética Molecular, Universidad de Valladolid-Consejo Superior de Investigaciones Científicas (IBGM, UVa-CSIC), 47003 Valladolid, Spain.ORCID 0000-0002-1707-4001
Alicia BarrosoHuman Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Victoria FernándezHuman Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Hugo Tejera-PérezHuman Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Guillermo PitaHuman Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Rocío Núñez-TorresHuman Cancer Genetics Programme, Human Genotyping Unit (CEGEN), Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Luz PomboMedical Oncology Section, Universitary Hospital Complex of Albacete, 02006 Albacete, Spain.
Rafael Morales-ChamorroMedical Oncology Section, Hospitalary Compex La Mancha Centro, 13600 Alcázar de San Juan, Spain.
Juana María Cano-CanoMedical Oncology Service, Universitary General Hospital of Ciudad Real, 13005 Ciudad Real, Spain.
Maria Del Carmen SorianoOncology Service, Virgen de la Luz Hospital, 16002 Cuenca, Spain.
Pilar GarreMolecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.
Mercedes DuránCancer Genetics Group, Unidad de Excelencia Instituto de Biología y Genética Molecular, Universidad de Valladolid-Consejo Superior de Investigaciones Científicas (IBGM, UVa-CSIC), 47003 Valladolid, Spain.ORCID 0000-0002-6301-9732
María Currás-FreixesHuman Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Miguel de la HoyaMolecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.ORCID 0000-0002-8113-1410
Ana OsorioHuman Cancer Genetics Programme, Familial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0001-8124-3984
Spanish National Cancer Research Centre · ESHospital Clínico San Carlos · ESUniversidad de Valladolid · ESHospital General Universitario de Ciudad Real · ESHospital San Juan de la Cruz · ESHospital Virgen de la Luz · ES

Funding

Centre for Biomedical Network Research on Rare DiseasesInstituto de Salud Carlos III PI19/00640Instituto de Salud Carlos III PI20/00110
6 · The paper itself

Abstract

Around 50% of the familial breast cancer (BC) cases are estimated to be caused by germline variants in known low-, moderate-, and high-risk susceptibility genes, while the other half is of unknown genetic origin. In the present study, we wanted to evaluate the role of the RECQ helicases, some of which have been studied in the past as candidates, with unclear results about their role in the disease. Using next-generation sequencing (NGS) technology, we analyzed the whole coding sequence of

Indexed as

BRCAXbreast cancer (BC)next-generation sequencingRECQ helicase family

Identifiers

PMID36230663
PMCPMC9563930
OpenAlexW4297464160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.